Cargando…

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

BACKGROUND: Type 2 diabetes may occur as a result of HIV infection and/or its treatment. Gliclazide is a widely used drug for the treatment of type 2 diabetes. Efavirenz and nevirapine are widely used non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. The role of Efa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastan, SK, Kumar, K Eswar
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765430/ https://www.ncbi.nlm.nih.gov/pubmed/19825151 http://dx.doi.org/10.1186/1758-5996-1-15

Ejemplares similares

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
por: Mastan, S K, et al.
Publicado: (2009)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2016)

Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2018)

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals
por: Mbuagbaw, Lawrence, et al.
Publicado: (2016)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
por: Hecht, Markus, et al.
Publicado: (2015)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
por: Jordaan, Maryam A., et al.
Publicado: (2020)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study
por: Stringer, Jeffrey S. A., et al.
Publicado: (2010)

1252. A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada
por: de Wet, Joss, et al.
Publicado: (2022)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors
por: BHARDWAJ, Nivedita, et al.
Publicado: (2020)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
por: Wright, David W., et al.
Publicado: (2012)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
por: Zhuang, Chunlin, et al.
Publicado: (2020)

Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2014)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Abstracts from the current global literature: Mitochondrial toxicities due to nucleoside reverse transcriptase inhibitors
por: Jain, Sonia, et al.
Publicado: (2012)

Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy
por: Tang, Li, et al.
Publicado: (2017)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
por: Petrou, Anthi, et al.
Publicado: (2019)

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV
por: De Francesco, Davide, et al.
Publicado: (2021)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_svct2t5c4kor14pcedkgjhq5b8